Turning to our updated 2024 outlook, we're pleased to have closed the acquisition of Alimera and are raising our full year 2024 guidance to reflect continued strength in purified Cortrophin Gel and the contribution from ILUVIEN and YUTIQ starting September 16. Our updated guidance is as follows: full year 2024 net revenues of $594,000,000 to 602,000,000 dollars up from our prior guidance of $540,000,000 to $560,000,000 representing year over year growth of approximately 22% to 24%. Protofen net revenues of $196,000,000 to $200,000,000 up from our prior guidance of $185,000,000 to $195,000,000 representing growth of 75 percent to 78%. Combined ILUVIEN and YUTIQ net revenues of $30,000,000 to $32,000,000 which reflects revenues during the post close period of September 16 through December 31. Adjusted non GAAP EBITDA of $149,000,000 to $153,000,000 dollars up from our prior guidance of $140,000,000 to $150,000,000 representing growth of approximately 11% to 14% and adjusted non GAAP earnings per share between $4.90 $5.05 up from our prior guidance of $4.38 $4.82 We now expect total company non GAAP gross margin to be at the high end of our previously communicated range of between 61% 62%.